FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Pat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/27/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. DRI
8. RKLB
9. SPCX
10. NKE

Go back to FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Pat
Merck & Co. (NYSE: MRK) Delayed: 128.66 +3.21 (2.56%)
Previous Close $125.45    52 Week High $65.46 
Open $125.83    52 Week Low $47.97 
Day High $128.78    P/E 87.52 
Day Low $125.83    EPS $1.47 
Volume 18,891,511